R&D Trends

GeNeuro, Servier partner for multiple sclerosis

Wednesday, December 3, 2014 12:57 PM

GeNeuro, a Switzerland-based developer of new therapies for neurology and autoimmune disorders, has entered into a strategic partnership with Servier, an independent French pharmaceutical company, to develop and market GNbAC1 in multiple sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.

More... »


Evotec, Sanofi to collaborate

Wednesday, December 3, 2014 12:55 PM

Evotec has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. The collaboration will comprise three major strategic initiatives all focused on improving innovation effectiveness in the drug discovery and preclinical development space.

More... »


Aeterna Zentaris, Sinopharm A-Think ink agreement

Monday, December 1, 2014 12:52 PM

Aeterna Zentaris, a specialty biopharmaceutical company based in Québec, and China-based Sinopharm A-Think Pharmaceuticals have signed of an exclusive license and technology transfer agreement for Aeterna Zentaris’ lead anti-cancer compound, zoptarelin doxorubicin, for the initial indication of endometrial cancer for the Chinese, Hong Kong and Macau markets (the territory). Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, currently is in a ZoptEC (zoptarelin doxorubicin in endometrial cancer) phase III trial in endometrial cancer.

More... »

Cancer Research U.K., AstraZeneca to collaborate

Monday, December 1, 2014 12:48 PM

AstraZeneca and Cancer Research U.K. have signed a memorandum of understanding through which Cancer Research U.K. drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AZ MRC U.K. Center for Lead Discovery to be built in Cambridge.

More... »

Merck, NewLink Genetics collaborate on investigational Ebola vaccine

Wednesday, November 26, 2014 11:54 AM

Merck and Ames, Iowa-based NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.

More... »

Report: AML treatment market to witness modest growth by 2020

Wednesday, November 26, 2014 11:53 AM

The value of the global acute myeloid leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, according to New York-based business intelligence provider GBI Research.

More... »

Global Ebola relief effort not reaching rural communities

Wednesday, November 26, 2014 11:50 AM

Unprecedented levels of donation to support Ebola-struck Sierra Leone are bypassing many of the places where funding is urgently needed, claim two U.K.-based experts. The independent experts, Dutch sustainability scientist Robert Verkerk, Ph.D., and Sierra Leonean crisis management expert Morris Marah, have just returned from a one-week capacity assessment mission requested by Hon Alpha Kanu, Minister of Information and Communications of Sierra Leone.

More... »

Yabao Pharmaceuticals, MRC Technology partner in China

Wednesday, November 26, 2014 11:49 AM

China-based Yabao Pharmaceutical has inked an exclusive license with MRC Technology, a U.K. medical research charity, to discover, develop and commercialize innovative products targeting a kinase target for neurodegeneration for the treatment of Parkinson's disease.

More... »

Cell Therapy Catapult, partners launch U.K. database of research funding

Monday, November 24, 2014 02:50 PM

The Cell Therapy Catapult, focused on the development of the U.K. cell therapy industry, has collaborated with the U.K. Regenerative Medicine Platform, the Knowledge Transfer Network and the Association of Medical Research Charities to develop a database of U.K. cell therapy research funding.

More... »

Gates Foundation to support Ebola-affected countries, accelerate treatment evaluation

Monday, November 24, 2014 02:46 PM

The Bill & Melinda Gates Foundation, based in Seattle, Wash., will be supporting efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus. Various drug candidates also will be evaluated, including the experimental antiviral drug brincidofovir.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs